You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Selective CYP26 inhibitors for the oral treatment of recalcitrant nodular acne.

    SBC: DERMAXON LLC            Topic: NIAMS

    Project Summary / Abstract DermaXon's project goal is to develop efficacious, substrate-based, selective inhibitors of CYP26s, the enzymes responsible for the metabolism of all-trans retinoic acid (atRA) in the epidermis, as an oral treatment for severe recalcitrant acne. This approach will provide an improved acne therapeutic without the adverse effects associated with currently marketed retinoid ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Booth™ by Opio™: Developing technology to expand the reach of opioid treatment programs into rural and underserved areas.

    SBC: Opio Connect, Inc.            Topic: NIDA

    The goal of this project is to develop a treatment booth with technology that allows opioid treatment programs to remotely dispense, either methadone or buprenorphine, under medical observation through telemedicine to a patient in a treatment booth. We believe that robotic automation is the ideal application to perform the same mechanical functions of the nurse at the dosing window. Specifically, ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Pharmacogenomics Workflow: Identifying Biomarkers and Treatment Options

    SBC: Golden Helix, Inc.            Topic: 172

    Abstract Pharmacogenomics, the study of how an individual's genetic makeup affects their response to drugs, has undergone rapid advancements. This has occurred alongside a decrease in the cost of genotyping technology, making implementation of pharmacogenomics into clinical practice increasingly feasible. Personalized medicine leveraging pharmacogenomics is gaining momentum to optimize drug choice ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)

    SBC: NANOVALENT PHARMACEUTICALS INC            Topic: 102

    Project Summary The goal of this Fast Track STTR project is to determine proof-of-principle and efficacy of a novel blood brain barrier (BBB) penetrating therapeutic nanoparticle for the potential treatment of otherwise intractable brain tumors like glioblastoma multiforme (GBM). This project seeks to demonstrate that novel, targetable nanoparticles can delivery therapeutic substances to human bra ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Booth™ by Opio™: Developing technology to expand the reach of opioid treatment programs into rural and underserved areas.

    SBC: Opio Connect, Inc.            Topic: NIDA

    The goal of this project is to develop a treatment booth with technology that allows opioid treatment programs to remotely dispense, either methadone or buprenorphine, under medical observation through telemedicine to a patient in a treatment booth. We believe that robotic automation is the ideal application to perform the same mechanical functions of the nurse at the dosing window. Specifically, ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Post assembly balancing of Y-Branch splitters used in IFOG sensors

    SBC: ADVR, INC.            Topic: N221078

    In this SBIR program, AdvR will develop a new feature in Y-branch dual phase modulator IOCs which enables fine tuning of the split ratio after assembly.  The proposed approach utilizes existing technology with a long flight heritage in tactical gyroscopes to create a tunable section which is localized, finely adjustable and permanent after tuning.  Preliminary modeling indicates the target perfo ...

    SBIR Phase I 2022 Department of DefenseNavy
  7. Live Cell Fluorescent Assays for SARS-CoV-2 protease activity and COVID-19 Drug Discovery

    SBC: MONTANA MOLECULAR LLC            Topic: NIAID

    SUMMARY STATEMENT The SARS-CoV-2 virus depends upon two proteases for replication, 3CLpro and PLpro. If one or both of these proteases can be blocked, COVID-19 infection can be effectively treated. Montana Molecular makes and sells live cell, fluorescent biosensor assays for disease research and drug discovery. In response to the COVID-19 pandemic, Montana Molecular applied its expertise and backg ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Beartooth MK II TAK Mesh Radio, Low SWapC, LPD, LPI

    SBC: BEARTOOTH RADIO, INC.            Topic: DTRA212008

    Beartooth MK II is a small, inexpensive, disposable system for warfighter communication.  The system enables the warfighter to sense and respond to the environment, threats, and targets.  Beartooth has a low probability of detection, low probability of interception and applies artificial intelligence to increase warfighter lethality and survivability while lowering cognitive load.  The sys ...

    SBIR Phase I 2022 Department of DefenseDefense Threat Reduction Agency
  9. Development of a Selective Inhibitor of NaV1.7 for the Treatment of Ocular Pain

    SBC: SITEONE THERAPEUTICS, INC.            Topic: NEI

    PROJECT SUMMARY The absence of safe and effective strategies for the management of ocular pain is motivating the development of a novel topical drug suitable for patient self-administration. Conventional local anesthetics, such as proparacaine, inhibit voltage-gated sodium channels (NaV) and are highly effective for the management of ocular pain in acute, in-office settings. However, these anesthe ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Discovery of NaV1.7 Inhibitors for the Treatment of Pain

    SBC: SITEONE THERAPEUTICS, INC.            Topic: 105

    PROJECT SUMMARY The objective of our program is to develop a safe and effective nonopioid analgesic for the treatment of neuropathic pain, such as pain associated with chemotherapy-induced peripheral neuropathy, that targets an isoform of the voltage-gated sodium ion channel, NaV1.7. Voltage-gated sodium channels are involved in the transmission of nociceptive signals from their site of origin in ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government